CHAMPIONS ONCOLOGY, INC. Cash and Equivalents

Quick Answer

CHAMPIONS ONCOLOGY, INC. reported Cash and Equivalents of $3.24 million for fiscal year 2019.

CHAMPIONS ONCOLOGY, INC. Cash and Equivalents — Annual History

Fiscal Year Cash and Equivalents YoY Change
2019 $3.24M +278.2%
2018 $856.0K -74.0%
2017 $3.29M +27.5%
2016 $2.58M -72.4%
2015 $9.36M +58.8%
2014 $5.89M -38.4%
2013 $9.56M +101.1%
2012 $4.75M -54.5%
2011 $10.46M +306.6%
2010 $2.57M

Quarterly Cash and Equivalents

Quarter Ending Cash and Equivalents YoY QoQ
January 31, 2026 $7.13M +122.6% -16.3%
October 31, 2025 $8.52M +209.2% -17.5%
July 31, 2025 $10.32M +257.0% +5.5%
April 30, 2025 $9.79M +273.8% +205.6%
January 31, 2025 $3.20M -28.3% +16.3%
October 31, 2024 $2.75M -50.0% -4.8%
July 31, 2024 $2.89M -40.6% +10.5%
April 30, 2024 $2.62M -74.1% -41.4%
  • CHAMPIONS ONCOLOGY, INC. showed an increase of +278.2% in Cash and Equivalents compared to the prior fiscal year.
  • Over the 2010–2019 period, CHAMPIONS ONCOLOGY, INC.’s cash and equivalents has grown by 25.9% (from $2.57 million to $3.24 million).
  • The most recent figure is from CHAMPIONS ONCOLOGY, INC.’s fiscal year 2019 report (Form 10-K), filed with the SEC on July 29, 2019.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment